In summary, bronchiectasis complications include frequent exacerbations, cardiovascular events, hemoptysis, nontuberculous mycobacterial lung infections, respiratory failure, and even death.

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while ...

Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and hospitalization within 2 years of diagnosis, according to results published in BMC ...

Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis ...

FDA grants Priority Review for Insmed’s brensocatib for treatment of bronchiectasis with PDUFA target action date set for August 12, 2025. News release. Insmed. February 6, 2025.

Participants with suspected bronchiectasis had a 15% higher risk for 10-year mortality compared with those without airway thickening (difference in mortality probability, 0.15; 95% CI, 0.09 to 0.21).

Fewer patients with bronchiectasis vs. COPD had at least one cardiovascular comorbidity/risk factor, according to results published in Respiratory Medicine.“Subjects with bronchiectasis may ...

Bronchiectasis, a condition defined by widened lung airways, cough and sputum production, and frequent infections, often presents along with chronic obstructive pulmonary disease (COPD). This ...

New drug shows promise for treating bronchiectasis Date: May 2, 2025 Source: University of Connecticut Summary: Results of a large, global clinical trial spanning five continents with over 1,700 ...

Brensocatib is an oral, selective, competitive, and reversible inhibitor of DPP-1. 19 In the phase 2 WILLOW trial involving adults with bronchiectasis, treatment with a 10-mg or 25-mg dose of ...

Change from baseline in the Quality of Life Bronchiectasis (QOL-B) Respiratory score: 2 points (P =.0594) and 3.8 points (P =.0004; nominal significant p-value).